Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Rising IV Doses of Sabiporide in Healthy Males
NCT02224079Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2002
- Primary completion
- Jun 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of sabiporide in myocardial infarction (MI) and Myocardial ischemia (MI), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with adverse events up to 12 days, Number of subjects with clinically significant findings in vital signs up to 12 days and 2 more. Started Apr 2002; status: completed.
02
Drugs
sabiporide
03
Conditions
myocardial infarction (MI)Myocardial ischemia (MI)
Beyond the preview
Go deeper on NCT02224079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224079.